I

n a damning report, a major shareholder advisory firm is recommending that Mylan stockholders vote to remove 10 incumbent board members — including non-executive chairman Robert Coury and chief executive officer Heather Bresch — over the EpiPen pricing scandal and subsequent investigations. The company holds its annual meeting on June 22.

In explaining its recommendations, Institutional Shareholder Services argued the Mylan board is responsible for “significant destruction” in shareholder value and “material failures” over a number of years to respond to “warning signs,” but failed to take action to mitigate or head off the risks. As a result, the company also suffered “long-term reputational damage.”

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.